A compilation of news articles in the field of gynecologic oncology and recent scientific studies
As cancer tears through Africa, drug makers draw up battle plan
October 7, 2017: New York Times – “Under the new agreement, the companies — Pfizer, based in New York, and Cipla, based in Mumbai — have promised to charge rock-bottom prices for 16 common chemotherapy drugs. The deal, initially offered to a half-dozen countries, is expected to bring lifesaving treatment to tens of thousands who would otherwise die.” Read the NY Times article.
Death rates dropping, but racial disparities remain in breast cancer
October 3, 2017: Oncology Nursing News – According to a recent study released by the American Cancer Society, “From 2006 to 2015, there was a decrease in deaths in all groups. But, the death rate among non-Hispanic Black women continued to be higher than non-Hispanic white women.” Read more.
Dr. Ginsburg on genetic testing guidelines for gynecologic malignancies
October 3, 2017: Onc Live – Dr. Ophira Ginsburg in a video interview regarding NCCN guidelines for genetic testing. See the interview.
Celsion announces final clinical and traslational research data from its OVATION study at the AACR special conference on ovarian cancer
October 3, 2017: Global Newswire – “Final clinical and translational research data from its OVATION Study, a Phase Ib dose escalating clinical trial combining GEN-1, the Company’s DNA-based immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with advanced Stage III/IV ovarian cancer who will undergo neoadjuvant chemotherapy followed by interval debulking surgery.” Read the press release.
ASTRO 2017: GOG-249 confirms adjuvant pelvic radiation as standard of care for high-risk, early stage endometrial cancer
September 29, 2017: ASCO Post – “In a new phase III trial report from the National Clinical Trial Network group, NRG Oncology, recurrence-free and overall survival rates for women with stage I–II high-risk endometrial cancer were not superior following adjuvant vaginal cuff brachytherapy plus chemotherapy when compared with adjuvant pelvic radiation therapy.” Read more.
Acelarin-Paraplatin combo shows high disease control rates in phase 1b trial for ovarian cancer
September 29, 2017: Ovarian Cancer News Today – “Nearly all ovarian cancer patients enrolled in NuCana‘s Phase 1b trial benefited from the combination of Acelarin (NUC-1031) plus Paraplatin (carboplatin), according to data presented at the recent European Society for Medical Oncology (ESMO) 2017 Congress in Madrid.” Read the article.
Third CDK blocker approved for breast cancer
September 28, 2017: MedPage Today – “The FDA approved abemaciclib (Verzenio) for treatment of hormone receptor-positive, HER2-negative breast cancers that have progressed while patients were on endocrine therapy.” Read more.
More expansive genetic testing needed in ovarian cancer
September 28, 2017: Cure Today – “More research is needed on the other genetic mutations, besides BRCA, that patients with ovarian cancer harbor so that they can be used to help plan treatments.” Read more.
Ovarian cancer care: What PCPs need to know
September 27, 2017: Healio interviews Dr. Stephanie Blank regarding primary care physicians and their role in prevention, screening of ovarian cancer and more. Read the interview.
Genelux initiates phase 2 clinical trial of GL-ONC1 in recurrent ovarian cancer
September 27, 2017: “Genelux Corporation, a privately-held biopharmaceutical company focused on the development of its proprietary oncolytic immunotherapy platform, today announced that it has treated the first patient in a Phase 2 clinical trial in recurrent ovarian cancer, with its lead clinical-stage candidate, GL-ONC1.” Read the press release.
Pelvic radiation remains standard treatment for early-stage endometrial cancer
September 26, 2017: Healio – “Vaginal cuff brachytherapy with chemotherapy did not extend RFS or OS compared with pelvic radiation therapy for women with stage I or stage II high-risk endometrial cancer, according to phase 3 results of the Gynecology Oncology Group-249 trial presented at the American Society for Radiation Oncology Annual Meeting.” Read the article.
Marcus E. Randall, MD, on endometrial cancer: results from a gynecology oncology group study
September 2017: ASCO Post – “A video interview with Dr. Randall on the phase II study findings on pelvic radiation therapy vs vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy in patients with high-risk, early stage endometrial cancer.” Watch the video.
Solange Peters, MD, PhD and Mary Gospodarowicz, MD, on mentoring women in oncology: an international perspective
September 2017: ASCO Post – A video interview with Dr. Mary Gospodarowicz, a recipient of the 2017 Women who Conquer Cancer Mentorship Award. See the interview.
New hope for ovarian cancer
September 25, 2017: Mayo Clinic – interview with an ovarian cancer survivor discussing the new treatments available and the hope they bring. Read the piece.
The high cost of new cancer therapies – a challenge of inequality for all countries
September 2017: JAMA Network – Viewpoint article on the high cost of cancer drugs and the need to take action. Login required to Read the full article.
The HPV vaccine gains ground amoung US teenagers
September 22, 2017: New York Times – “More than half of all American teenagers are getting vaccinated against human papillomavirus, and the rate is rising over time, according to a new report from the Centers for Disease Control and Prevention.” Read more.
Bevacizumab extends survival in advanced cervical cancer
September 22, 2017: Healio – “The addition of bevacizumab to chemotherapy continued to show significant survival benefits in women with advanced cervical cancer, according to final analysis of a randomized, open-label, phase 3 trial published in The Lancet.” Read more.
New genetic test for predicting cancer recurrence
September 21, 2017: Medical Xpress – “Researchers have discovered a new genetic test which could help predict cancer recurrence – paving the way for more precise, personalised treatments.” Read more.
HPV self-sampling could boost cervical cancer screening rates in transgender men
September 20, 2017: Healio – “Transgender men are less likely to be screened for cervical cancer than cisgender women. About half of the transgender men surveyed reported they had not received a Pap smear within the past 3 years.” Read more.
Gardasil 9 vaccine seen as effective cervical cancer combatant, study finds
September 15, 2017: Life Science Daily – “Results determined Gardasil 9 showed 97.4 percent efficacy to prevent infections and disease caused by the five additional HPV genotypes not included in the four-valent Gardasil vaccine.” Read more.
ESMO 2017: Study confirms chemoradiation is best treatment for locally advanced cervical cancer
September 14, 2017: ASCO Post – A 14-year randomized trial in more than 600 patients has concluded that chemoradiation should remain the standard treatment for patients with locally advanced cervical cancer. The findings were reported at the European Society for Medical Oncology (ESMO) 2017Congress in Madrid (Abstract 928O_PR). Read more.
Avastin Clone OK’d – Biosimilar for bevacizumab approved for various cancers
September 14, 2017: MedPage Today – “Amgen’s biosimilar for the angiogenesis-inhibiting biologic drug bevacizumab, to be sold as Mvasi, was approved…by the FDA.” Read more.
The crisis in gynecologic cancer research
September 14, 2017: This New York Times editorial discusses the drop in the number of gynecologic cancer clinical trials by 90 percent from 2011 to 2016 in the United States. Read the story from the NYT.
Editorial Article: Epigenetic biomarkers in gynecological cancers explored
September 14, 2017: Dr. Lewis Francis, of Swansea University, discusses ChIP methods used in his research on the role of epigenetics in ovarian and endometrial cancers. Read the interview.
Multivitamins tied to reduced risk of chemo-induced neuropathy
September 13, 2017: HealthDay News — “Multivitamin use before diagnosis of breast cancer is associated with reduced risk of symptoms of chemotherapy-induced peripheral neuropathy (CIPN), according to a study published online September 1 in the Journal of the National Cancer Institute.” Read more.
Is genetic testing for cancer survivors underutilized?
September 13, 2017: “More than 80% of women with a history of either breast or ovarian cancer may not be receiving necessary genetic testing, according to a new study in the Journal of Clinical Oncology.” Read more.
Preventing cancer and other diseases caused by Human Papillomavirus infection: 2017 Lasker-DeBakey Clinical Research Award
September 12, 2017: JAMA Network – “The 2017 Lasker-DeBakey Clinical Medical Research Award has been presented to Douglas Lowy and John Schiller for development of the virus-like particle technology that was used to create the human papillomavirus vaccine to prevent cervical cancer and other diseases.” Read the article.
For many women, cervical cancer screening may get a lot simpler
September 12, 2017: NPR discusses the impact of the new draft recommendations from the US Preventative Services Task Force. Read the article.
Who is the current Minister of Health in Nigeria 2017?
September 12, 2017: Professor Isaac Adewole has recently taken over the position of minister of health in Nigeria. Before he was appointed to become the minister he was a Professor of Obstetrics and Gynaecology at the College of Medicine, University of Ibadan. Read more.
No PFS gain with dose-dense weekly chemotherapy in epithelial ovarian cancer
September 11, 2017: medwireNews: “The 3-weekly regimen of carboplatin and paclitaxel should remain the first-line standard of care for women with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, say the ICON8 researchers who did not find a progression-free survival (PFS) benefit with dose-dense weekly chemotherapy.” Read more.
Understanding racial disparities in endometrial cancer
September 10, 2017: Oncology Times – Dr. Kemi Doll “is ambitiously engaged in a multi-pronged, ‘360-degree’ research project to detect endometrial cancer diagnosis and treatment pathways, as well as the delay of the same, particularly for black women.” Read more.
A look at glucose metabolism in ovarian cancer
September 10, 2017: “A new study of non-diabetic women with ovarian cancer reveals a potential correlation and area for further study regarding the expression of the GLUT1 glucose transporter receptor at the cancer tissue level.” Read more about the study in Oncology Times.
Precision Medicine: A new era for ovarian cancer
September 10, 2017: Oncology Times published a study on genomics, clinical trial enrollment and research directions. Read the article.
Concomitant chemoradiation should be standard for locally advanced cervical cancer
September 10, 2017: Healio.com reports: “Neoadjuvant chemotherapy followed by radical surgery did not improve outcomes compared with cisplatin-based concurrent chemoradiation for women with locally advanced squamous carcinoma of the cervix, according to results of a randomized controlled trial presented at the European Society for Medical Oncology Congress.” Read more.
Reproductive potential can be maintained after ovarian tissue transplant
September 10, 2017: Healio.com reports: “Ovarian tissue preservation, subsequent transplantation and maintenance of reproductive potential may be feasible for women with breast cancer who have BRCA mutations, according to a retrospective analysis presented at the European Society for Medical Oncology Congress.” Read more.
Dr. Mirza on niraparib plus bevacizumab combo in ovarian cancer
September 10, 2017: Onc Live.com: “Mansoor Raza Mirza, MD discusses phase I results of a trial exploring the combination of niraparib (Zejula) and bevacizumab (Avastin) in patients with platinum-sensitive epithelial ovarian cancer.” See the video.
Nirapatib maintains quality of life in recurrent ovarian cancer
September 8, 2017: Oncology Nurse Advisor reports: “Administering niraparib to patients with recurrent ovarian cancer after a complete response (CR) or partial response (PR) to platinum-based chemotherapy may allow patients to continuously maintain their quality of life (QOL) during treatment, according to a study presented at the European Society for Medical Oncology (ESMO) 2017 Congress.” Read more.
New data confirms standard dosing of chemotherapy in ovarian cancer treatment
September 6, 2017: Women with ovarian cancer can safely stick to the standard 3-week dosing schedule for paclitaxel rather than boosting up to a weekly dose-dense regimen, according to results of the phase III ICON8 trial to be presented at the ESMO 2017 Congress in Madrid. Read more.
Five important updates in gynecologic cancer
September 1, 2017: Healio.com sums up five updates about screening and treatment of gyn cancers.
Cancer patients still facing lack of information about
August, 31, 2017: Patients undergoing cancer treatment are still not getting enough support when it comes to the impact that the disease and its treatment has on their fertility, a new study has discovered. Read more from FIGO news.
Does baby powder cause cancer? A jury says yes. Scientists aren’t so sure.
August 22, 2017: Read the story from NPR.
Palliative care reduces aggressive treatment of advanced cancer
August 22, 2017: Exposure to palliative care considerably reduced health care utilization among Medicare beneficiaries with advanced cancer, according to observational study results published in Journal of Oncology Practice. Read more from Healio.com.
Platinum therapy should not be delayed in ovarian cancer relapse
August 22, 2017: Platinum-based chemotherapy (PBC) should not be delayed in favor of non-platinum-based therapy (NPBC) in patients with partially platinum-sensitive ovarian cancer (OC), according to a study published in the Journal of Clinical Oncology. Read more from Cancer Therapy Advisor.
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
August 22, 2017: Nature Communications published a study online reporting analyses of 160 BRCA1 and BRCA2 germline mutation-associated breast and ovarian tumors. Read the study.
Lynparza receives additional FDA approval for ovarian cancer
August 21, 2017: From Managed Care: “The PARP inhibitor olaparib (Lynparza, AstraZeneca/Merck) has received FDA approval for a broader indication in ovarian cancer cases, including a new tablet formulation that will ease women’s pill burden.” Learn more about the specific approvals.
Addition of CA4P to bevacizumab confers modest PFS benefit in platinum-resistant ovarian cancer
August 17, 2017: Healio reports: “A second interim analysis of a trial designed to evaluate the addition of CA4P to standard therapy for patients with platinum-resistant ovarian cancer showed a small PFS benefit for the combination. However, the difference did not reach statistical significance.” Read more.
Clinical trial stirs controversy over power morcellator bags
August 16, 2017: “A clinical trial scheduled to evaluate the safety and efficacy of a bag designed to catch cancerous tissue from power morcellation in women undergoing laparoscopic hysterectomies has rekindled debate in the gynecologic community over the controversial procedure.” Read about the study on Healio.com.
Sexual dysfunction in women with cancer: a review of available interventions
August 15, 2017: Oncology Nurse Advisor reports: “According to a study published in the European Journal of Cancer Care, cancer diagnosis and treatment have varied social, psychological, and physical impact on sexual health and may decrease quality of life for women.” Read more.
Expert discusses promise of Mirvetuximab Soravtansine in ovarian cancer
August 14, 2017: Onc Live reports: “Mirvetuximab soravtansine (IMGN853) demonstrated a favorable toxicity profile and encouraging clinical activity in patients with epithelial ovarian cancer, according to a pooled analysis of phase I expansion cohorts that was presented at the 2017 ASCO Annual Meeting.” Read more.
Dr. Chase on future treatment landscape of gynecologic malignancies
August 10, 2017: Onc Live posted a video interview with Dana M. Chase on the future treatment landscape of gynecologic malignancies, including vulvar cancer, endometrial cancer, and cervical cancer. Watch the video.
Identifying essential genes for cancer immunotherapy
August 9, 2017: ASCO Post – “A new study published by Patel et al in Nature identifies genes that are necessary in cancer cells for immunotherapy to work—addressing the problem of why some tumors don’t respond to immunotherapy, or respond initially but then stop as tumor cells develop resistance to immunotherapy.” Read the discussion.
Dr. Arend discusses MSI testing in gynecologic malignancies
August 9, 2017: Onc Live posts a video interview with Dr. Rebecca Arend, MD regarding microsatellite instability (MSI) testing in patients with gynecologic malignancies. See the video.
Bevacizumab OS benefit confirmed in cervical cancer
August 8, 2017: Onc Live reports: “Adding bevacizumab (Avastin) to chemotherapy improved overall survival (OS) for women with cervical cancer, according to final results from the phase III GOG 240 trial published online in The Lancet.” Read more.
NCI study identifies essential genes for cancer immunotherapy
August 7, 2017: NIH – “A new study identifies genes that are necessary in cancer cells for immunotherapy to work, addressing the problem of why some tumors don’t respond to immunotherapy or respond initially but then stop as tumor cells develop resistance to immunotherapy.” Read more.
Opioid use common among cancer survivors
August 7, 2017: Healio reports: “Cancer survivors, even those 10 years or longer past diagnosis, had 1.22-times higher prescription opioid use than matched individuals without a history of cancer, according to results of a population-based study.” Read the Healio article. Read the original study.
New data address critical surgical questions in ovarian cancer
August 4, 2017: Dr. Maurie Markman discusses two abstracts presented at the 2017 ASCO meeting: LION Study (Lymphadenectomy in Ovarian Neoplasms) and Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer. Watch the video or read the transcript.
Surgeons and the opioid epidemic: Treatment and education strategies for the practicing surgeon
August 2, 2017: The American College of Surgeons released a bulletin to address issues surgeons are facing regarding opioids. The bulletin includes Implicit bias and the perception of pain, opioid treatment of chronic pain, opioid management training and a general approach to improved treatment of surgical pain. Read the bulletin.
Celsion announces latest translational data from the OVATION Study in newly diagnosed advanced ovarian cancer patients
August 2, 2017: Nasdaq reports: “findings from the translational research data from its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with the standard of care for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer who will undergo neoadjuvant chemotherapy (NACT) followed by interval debulking surgery.” Read the press release.
Lower body lymphedema in patients with gynecologic cancer
August 2017: This International Journal of Cancer Research and Treatment review “focuses on secondary lymphedema due to gynecologic cancer treatment, analyzing its incidence in the different types of gynecologic cancer, diagnosis, risk factors, impact on QoL and treatment.” Read the study.
77-year-old cancer patient undergoes robotic surgery
July 31, 2017: The Times of India reports the benefits of robotic surgery and an instance in which it was used for an ovarian cancer patient. Read the article.
Bristol-Myers Squibb, Clovis Oncology to evaluate nivolumab-rucaparib combination
July 31, 2017: Healio reports: Bristol-Myers Squibb and Clovis Oncology entered a clinical collaboration to evaluate the combination of nivolumab and rucaparib for treatment of three tumor types. The collaboration will include two pivotal phase 3 trials and one phase 2 trial designed to assess the PD-1 checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb) in combination with the PARP inhibitor rucaparib. Read more.
Is it possible to get pregnant after endometrial cancer? An oncologist explains
July 30, 2017: Kelly Mullen McWilliams blogs about uterine cancer and pregnancy. Read the blog.
Molecular similarities discovered among endometrial cancers
July 28, 2017: Healio reports: “Clear cell endometrial cancer appeared to have molecular similarities with serous endometrial cancer and endometrioid endometrial cancer, according to a study published in Cancer.” Read the article.
Researchers to present clinical data supporting use of Xoft System for endometrial cancer treatment at American Association of Physicists in Medicine Annual Meeting & Exhibition
July 27, 2017: EconoTimes reports: “Researchers from Miguel Servet University Hospital in Zaragoza, Spain will present preliminary findings from their recent clinical experience treating 36 endometrial cancer patients with electronic brachytherapy using the Xoft System at the AAPM meeting. The dosimetric analysis showed that electronic brachytherapy with the Xoft System delivered a lower dose of radiation to surrounding healthy organs at risk in patients with endometrial cancer, such as the bladder and rectum, than would have been delivered by treatment with Ir-192 or Co-60 sources.” Read more.
Challenges in international comparison of health care systems
July 27, 2017: The JAMA Netowrk published a “viewpoint” article on the differences between health care systems across the globe and how they can be compared despite these differences. Read the article.
Complementary cancer therapies: fatigue and exercise
July 27, 2017: Cure Today published an opinion piece on the positive impact of exercise for cancer patients and survivors. Read the article.
Olaparib tablets prolong progression-free survival in ovarian cancer
July 26, 2017: Cancer Therapy Advisor reports: “Maintenance treatment with olaparib tablets may prolong progression-free survival (PFS) without negatively affecting quality of life among patients with relapsed ovarian cancer, according to a study published in The Lancet Oncology.” Read more
How PARP inhibitors might prove useful in more than just BRCA cancers
July 26, 2017: FierceBiotech reports: “Scientists led by the University of Pennsylvania believe Lynparza may be able to kill cancer cells that don’t have the mutations—provided it’s paired with a helper compound.” Read more.
Cancer patients in chemo ward may influence each other’s survival
July 25, 2017: Reuters Health reports: “Who a cancer patient spends time with in the chemotherapy ward may have a small but significant effect on their likelihood of surviving the disease, suggests a small study in the UK.” Read the article.
Doctors receiving training in cervical cancer surgery
July 24, 2017: The Himalayan Times report that “doctors of Bhaktapur Cancer Hospital and Nepal Cancer Relief Society have been undergoing surgical training in gynecologic oncology from Health Volunteers Overseas, USA.” Read more.
Breast cancer due to non-brca1 and non-BRCA2 mutations in Ashkenazi Jewish Women
July 20, 2017: JAMA Network posts an audio file of an interview with Mary-Claire King, author of Genetic Predisposition to Breast Cancer Due to Mutations other than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. Listen to the interview.
Nivolumab active in advanced gynecologic cancers
July 19, 2017: Onc Live reports: from ASCO 2017: “In phase I/II results from CheckMate-358, nivolumab (Opdivo) demonstrated clinical activity in women with recurrent/metastatic cervical cancer, and was active to a lesser extent in vaginal and vulvar cancers.” Read more.
Task force maintains recommendation against ovarian cancer screening
July 18, 2017: Drs. Maurie Markman and Richard Penson agree with the US Preventative Services Task Force advising “against screening for ovarian cancer in women who have no signs or symptoms, noting that screening does not decrease the number of deaths from ovarian cancer and may lead to women having unnecessary surgery.” Read more.
FDA ODAC recommends biosimilar bevacizumab and trastuzumab
July 18, 2017: The European Society for Medical Oncology reports the recent FDA recommendation regarding these two drugs. Read more.
Preventative mastectomies provide little survival benefit for ovarian cancer patients, study finds
July 17, 2017: Ovarian Cancer News Today reports: “Mastectomies and the removal of ovaries and fallopian tubes are considered preventive measures for women carrying BRCA genetic mutations linked to breast and ovarian cancer. But for women who have already had ovarian cancer, a risk-reducing mastectomy is not cost-effective and provides few survival benefits, according to researchers at Duke University Medical Center.” Read more.
Rethinking the ASCO Resource Stratified Cervical Cancer Screening Guidelines in the context of existing health infrastructure in basic settings
July 17, 2017: The Journal of Clinical Oncology publishes a response to the ASCO guideline challenging two of the recommendations the believe overlook opportunities to use existing health infrastructure in low- and middle-income countries. Read the correspondence.
With cancer screening, better safe than sorry?
July 17, 2017: The New York Times editorial discusses the risks and benefits of cancer screening as well as providing a list of US screening guidelines for different cancers. Read the article.
High-grade dysplasia increases long-term risk for HPV-related cancers
July 17, 2017: Healio.com reports: “Women maintained an increased risk for premalignancies and carcinomas of the anus, vulva, vagina and oropharynx 20 years after cervical intraepithelial neoplasia grade 3 diagnosis, according to results of a population-based study.” Read more.
Novel agent produces highest OS to date in PRmCC
July 14, 2017: Clinical Oncology reports: “Data from a multicenter trial of a novel targeted immunotherapy for the treatment of persistent/recurrent or metastatic cervical cancer (PRmCC) have yielded historic results: a 12-month overall survival (OS) of 38%, exceeding OS rates of more than 20 other clinical trials conducted in this area over nearly two decades.” Read more.
Cervical Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
July 13, 2017: Annals of Oncology publishes ESMO cervical cancer guidelines focusing on the management, follow-up, long term implications and survivorship as well as a new treatment algorithm. Read the guidelines.
Clinical trials are the way forward for ovarian cancer, but they need advocates at every level
July 9, 2017: Cure Today reports: “For women with ovarian cancer, the message is clear: participating in clinical trials, even early-phase ones, offers the best hope for better treatments, but efforts are urgently needed at every level to ensure that more of these research opportunities are available.” Read more.
The road ahead for ovarian cancer
July 8, 2017: Cure today reports: “Opening the 20th Annual Ovarian Cancer National Conference in Chicago, John Moroney, M.D., underscored the challenges that remain in the early detection and treatment of ovarian cancer, but also the tremendous hope that resides in robust clinical trial research.” Read the full article with more quotes from Dr. Moroney.
Incidence and prevalence of cancer in Colombia: the methodology used matters
July 6, 2017: Study published in ASCO’s Journal of Global Oncology compares real-world data from the health care system and estimates from cancer registries to determine a more precise estimation of patients with cancer in Colombia. Read the study.
Rates of pregnancy significantly lower in cancer survivors compared with general population
July 6, 2017: Oncology nurse advisor reports: A large scale population study revealed that girls and women aged 39 years and younger may be up to 38% less likely to achieve pregnancy after surviving cancer vs patients who have never had cancer. Read more.
Web-based symptom self-reporting improves survival
July 6, 2017: ClinicalOncology.com reports: “Having patients proactively report symptoms through a web-based tool improved survival in patients receiving routine outpatient chemotherapy, according to results from a Phase III trial. The approach increased median overall survival by five months compared with usual care.” Read more.
HPV triage after abnormal cervical cytology detects CIN earlier
July 5, 2017: Cancer Network reports “Women who undergo human papillomavirus (HPV) testing following a test showing abnormal cytology have earlier detection of high-grade cervical intraepithelial neoplasia (CIN), compared to those who do not undergo HPV testing, according to a new study. The higher rates of detection come at the expense of increased biopsy and electrosurgical excision rates.” Read more.
Angle’s ovarian cancer test could beat current standard
July 5, 2017: “UK liquid biopsy group Angle has released trial findings that indicate its Parsortix blood test has the potential to out-perform the current standard of care in detecting ovarian cancer.” Read more.
PARP inhibitor shows promise in ovarian cancer
July 5, 2017: “Results of the ARIEL3 study of rucaparib (Rubraca) show promise for the drug’s potential in helping women with advanced ovarian cancer, according to Boulder, Colo.-based Clovis Oncology, a biopharmaceutical company that specializes in cancer treatments.” Read more.
Celsion announces completion of OVATION study and provides update on its immunotherapy trial in advanced stage III and IV ovarian cancer
July 5, 2017: GlobeNewswire reports “Celsion Corporation (NASDAQ:CLSN) today provided an update on its Phase Ib dose escalating clinical trial (the OVATION Study) combining GEN-1, the Company’s IL-12 gene-mediated immunotherapy, with neoadjuvant chemotherapy for the treatment of newly-diagnosed patients with Stage III and IV ovarian cancer followed by interval debulking surgery.” Read the announcement.
FDA grants orphan drug designation to ALM201 for ovarian cancer
July 5, 2017: Healio.com announces: “ALM201 (Almac Discovery) is a therapeutic peptide developed to imitate properties of the FKBPL protein, a naturally secreted protein that has effects on multiple tumor biology processes, including cancer stem cells and angiogenesis.” Read the announcement.